Enhancement of select cognitive domains with rosiglitazone implicates dorsal hippocampus circuitry sensitive to PPARγ agonism in an Alzheimer's mouse model

INTRODUCTION: Several clinical studies have tested the efficacy of insulin‐sensitizing drugs for cognitive enhancement in Alzheimer's disease (AD) patients, as type 2 diabetes (T2D) is a well‐recognized risk factor for AD. Pilot studies assessing FDA‐approved diabetes drugs in subjects with ear...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortez, IbDanelo, Hernandez, Caterina M., Dineley, Kelly T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882162/
https://www.ncbi.nlm.nih.gov/pubmed/33382528
http://dx.doi.org/10.1002/brb3.1973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882162/
https://www.ncbi.nlm.nih.gov/pubmed/33382528
http://dx.doi.org/10.1002/brb3.1973

Ejemplares similares